DeepMed Research

BioMS Technology Corp.

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

Phase 3

Terminated

Conditions: Multiple Sclerosis, Secondary Progressive

Interventions: Drug: MBP8298

First Posted Date: 2007-05-03

Last Posted Date: 2009-08-13

Lead Sponsor: BioMS Technology Corp.

Target Recruit Count: 510

Registration Number: NCT00468611

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy